Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Eventide Asset Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,902 shares of the biopharmaceutical company’s stock after selling 40,548 shares during the period. Eventide Asset Management LLC owned about 0.10% of Alnylam Pharmaceuticals worth $41,053,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ALNY. Engineers Gate Manager LP raised its stake in shares of Alnylam Pharmaceuticals by 28.5% during the second quarter. Engineers Gate Manager LP now owns 32,630 shares of the biopharmaceutical company’s stock valued at $10,640,000 after acquiring an additional 7,238 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its holdings in Alnylam Pharmaceuticals by 29.4% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 6,912 shares of the biopharmaceutical company’s stock valued at $2,254,000 after purchasing an additional 1,570 shares during the period. Boothbay Fund Management LLC raised its position in Alnylam Pharmaceuticals by 90.4% during the 2nd quarter. Boothbay Fund Management LLC now owns 19,213 shares of the biopharmaceutical company’s stock valued at $6,265,000 after purchasing an additional 9,123 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Alnylam Pharmaceuticals by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 199,316 shares of the biopharmaceutical company’s stock worth $64,995,000 after buying an additional 1,873 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of Alnylam Pharmaceuticals by 109.3% in the 2nd quarter. Quantinno Capital Management LP now owns 13,464 shares of the biopharmaceutical company’s stock worth $4,391,000 after buying an additional 7,032 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the sale, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. The trade was a 4.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 60,328 shares of company stock valued at $27,288,993. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Down 3.7%

Shares of NASDAQ ALNY opened at $397.55 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a 50-day moving average of $452.35 and a 200 day moving average of $406.45. The stock has a market cap of $52.52 billion, a P/E ratio of 1,656.46 and a beta of 0.30.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ALNY shares. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Royal Bank Of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Truist Financial raised their target price on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. HC Wainwright set a $570.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, Jefferies Financial Group decreased their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $482.71.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.